Although there is abundant evidence for efficacy of antidepressants, a substantial minority of patients show an unsatisfactory response, and cessation of medication because of adverse effects is common. The choice of what drug to prescribe for optimal response with minimum unwanted effects is largely a matter of taking an educated guess. Pharmacogenetics offers considerable potential to provide tools to aid targeted, rational prescribing. GENDEP has three closely interconnected major themes aimed to address these issues. The first is a large-scale multi-centre human pharmacogenomics study focussed on the prediction of therapeutic response to antidepressants and adverse effects. The second is a set of basic science studies using animal models and in vitro experiments, and the third is a programme of work to address the relevant ethical, social, and legal issues. This project will include an integrative analysis of the results of the transcriptomics and proteomics on the samples from the human, the rodent, and the in vitro studies, in order to identify biomarkers consistently identified across all of these experimental methodologies. This integrated project should lead to validated pharmacogenomic methods for symptom improvement, the prediction of response to psychiatric drug treatment and the reduction of adverse effects. We may also be able to make a beginning on identifying new targets for drug discovery. GENDEP will examine such associated issues as the views of service users regarding consent in human pharmacogenomics studies, a cost-benefit analysis of introducing pharmacogenomic theranostics, and the investigation of the potential impact of a new generation of pharmacogenomically tailored treatments on patients’ and consumers’ views and attitudes. A key feature of the entire project is the active research involvement of stakeholders, including psychiatric service users, practising clinicians and industrial partners.
Partner CR9, responsabile scientifico per l'Università di Milano. Responsabile per la coordinazione del Task Force Group 4 (Functional genomics and proteomics of rat models of depression) di Progetto del 6º Programma Quadro, Unione Europea. "Genome-based therapeutic drugs for depression" (GENDEP)(2004 Jan 01).
Partner CR9, responsabile scientifico per l'Università di Milano. Responsabile per la coordinazione del Task Force Group 4 (Functional genomics and proteomics of rat models of depression) di Progetto del 6º Programma Quadro, Unione Europea. "Genome-based therapeutic drugs for depression" (GENDEP)
2004
Abstract
Although there is abundant evidence for efficacy of antidepressants, a substantial minority of patients show an unsatisfactory response, and cessation of medication because of adverse effects is common. The choice of what drug to prescribe for optimal response with minimum unwanted effects is largely a matter of taking an educated guess. Pharmacogenetics offers considerable potential to provide tools to aid targeted, rational prescribing. GENDEP has three closely interconnected major themes aimed to address these issues. The first is a large-scale multi-centre human pharmacogenomics study focussed on the prediction of therapeutic response to antidepressants and adverse effects. The second is a set of basic science studies using animal models and in vitro experiments, and the third is a programme of work to address the relevant ethical, social, and legal issues. This project will include an integrative analysis of the results of the transcriptomics and proteomics on the samples from the human, the rodent, and the in vitro studies, in order to identify biomarkers consistently identified across all of these experimental methodologies. This integrated project should lead to validated pharmacogenomic methods for symptom improvement, the prediction of response to psychiatric drug treatment and the reduction of adverse effects. We may also be able to make a beginning on identifying new targets for drug discovery. GENDEP will examine such associated issues as the views of service users regarding consent in human pharmacogenomics studies, a cost-benefit analysis of introducing pharmacogenomic theranostics, and the investigation of the potential impact of a new generation of pharmacogenomically tailored treatments on patients’ and consumers’ views and attitudes. A key feature of the entire project is the active research involvement of stakeholders, including psychiatric service users, practising clinicians and industrial partners.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
